SEHK:1530Biotechs
Assessing 3SBio (SEHK:1530) Valuation After Strong 2025 Earnings And Affirmed Dividend
Why 3SBio’s latest earnings and dividend decision matter
3SBio (SEHK:1530) has drawn fresh attention after reporting full year 2025 results alongside a reaffirmed final dividend. This combination puts both profitability and cash returns to shareholders in focus.
The company reported sales of CNY 17,695.75 million and net income of CNY 8,482.16 million for 2025, with basic earnings per share from continuing operations at CNY 3.51 and diluted earnings per share at CNY 3.43.
See our latest...